Lamogin 2 mg contains Lamotrigine, a well-established antiepileptic and mood-stabilizing medication. It is primarily indicated for the management of epilepsy, including partial-onset seizures, generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome, in both adults and children. Additionally, Lamotrigine is used in bipolar disorder for the prevention of depressive episodes. The 2 mg dosage is typically used as a starter or titration dose to minimize the risk of adverse effects, particularly severe skin reactions, when initiating therapy.

Therapeutic Class

Antiepileptic / Mood Stabilizer

Pharmacology

Lamotrigine acts by inhibiting voltage-sensitive sodium channels, stabilizing hyperexcitable neuronal membranes, and reducing the excessive release of excitatory neurotransmitters such as glutamate and aspartate. This mechanism prevents repetitive neuronal firing, which is a key factor in seizure activity.

Key pharmacokinetic properties:

• Oral absorption is rapid and nearly complete, with peak plasma levels reached in 1–3 hours

• Bioavailability: Approximately 98%, unaffected by food intake

• Protein binding: About 55%

• Metabolism: Mainly through hepatic glucuronidation

• Elimination half-life: 25–33 hours in adults, shorter in children, and prolonged when co-administered with valproate

• Excreted primarily in urine as glucuronide metabolites

The low sedative effect and minimal cognitive impairment make Lamogin suitable for long-term management of epilepsy and mood disorders.

Indications

Lamogin Tablet 2 mg is indicated for:

• Initiation and titration in adults and pediatric patients (≥2 years) with partial-onset seizures

• Generalized tonic-clonic seizures

• Seizures associated with Lennox-Gastaut syndrome

• Maintenance therapy in bipolar disorder, especially for the prevention of depressive episodes

Dosage and Administration

Adults (Seizures):

• Initial dose: 2 mg or 25 mg once daily depending on patient requirements and titration protocol

• Dose is gradually increased over 5–6 weeks to reduce the risk of rash and other adverse effects

• Target maintenance dose: 100–200 mg/day in divided doses; maximum 500 mg/day

Pediatric Patients:

• Dose initiation is weight-based, often starting with 0.15–0.2 mg/kg/day

• Titration occurs weekly based on clinical response and tolerability

Bipolar Disorder:

• Start at 2 mg daily and titrate slowly to 200 mg/day (or adjusted based on co-medications)

• Gradual titration is crucial to prevent severe dermatologic reactions

Administration Notes:

• Tablets should be swallowed whole with or without food

• Abrupt discontinuation may precipitate seizures; doses should be tapered gradually

• Consistent daily use improves therapeutic outcomes

Contraindications

• Hypersensitivity to Lamotrigine or any excipients

• History of serious skin reactions to Lamotrigine

Side Effects

Common side effects include:

• Dizziness, headache, fatigue, and blurred vision

• Nausea, vomiting, and gastrointestinal upset

• Mild rash; severe rash may indicate Stevens-Johnson syndrome or toxic epidermal necrolysis

• Ataxia, tremor, and rarely hematologic abnormalities

Precautions and Warnings

• Monitor patients for serious skin reactions, particularly during early therapy or rapid dose escalation

• Use with caution in patients with hepatic or renal impairment

• Monitor for suicidal ideation in patients with mood disorders

Pregnancy and Lactation

• Pregnancy Category C: Use only if clearly needed

• Lamotrigine passes into breast milk; nursing mothers should exercise caution

Storage Conditions

Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.

Mode of Action

Lamotrigine stabilizes neuronal membranes through sodium channel inhibition and decreases excitatory neurotransmitter release, preventing seizures and stabilizing mood in bipolar disorder. The 2 mg dosage is specifically used for safe initiation and titration to reduce adverse effects.